COMPANY Data
Movers and SHAKERS

Ticker | LCTX (AMERA) |
Current Price | $2.18 ↓ -0.11 |
Market Cap | 326.96M |
Price Target | $4.00 |
Volume | 640.15k |
52wk Range | $0.70 - $3.14 |
ADVANCED MARKET DATA |

Advanced Market Data
Lineage Cell Therapeutics, Inc. (LCTX)





Overview
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
- Industry/Sector Report
- Corporate Presentation
- Corporate Events
- Press Releases/News Feed
- ChannelCAST Videos [3]
- Senior Equity Research Analyst
- Corporate Filings
Lineage Cell Therapeutics, Inc. Corporate Filings
Lineage Cell Therapeutics, Inc. Corporate Events
Lineage Cell Therapeutics, Inc. Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available
Noble Capital Markets Analyst
FINRA licenses 7, 63, 86, 87.
Full Bio & Coverage List